Abstract
BackgroundSub-analysis of the adaptive CRT (aCRT) trial demonstrated the potential benefits of the aCRT algorithm over conventional echo-guided bi-ventricular (BiV) pacing in patients with left bundle branch block (LBBB) with moderately wide QRS (120–149 ms) and normal atrioventricular (AV) conduction. MethodsAdoption of Adaptive CRT in Patients with Left Bundle Branch Block and Moderately Wide QRS (aCRT MID-Q, UMIN Clinical Trials Registry Number: 000022452) was a multicenter, prospective, randomized, double-blind study designed to investigate the superiority of the aCRT pacing algorithm compared to echo-guided BiV pacing in patients with moderately wide LBBB and normal AV conduction. The primary endpoint was the improvement in clinical composite score (CCS) at 6 months; the secondary endpoints were changes in left ventricular (LV) end-systolic volume, LV ejection fraction, New York Heart Association classification, 6-min walk distance, and quality of life from baseline to 6 months post-randomization; heart failure administration; all-cause mortality; and cardiac mortality within 12 months. ResultsThe trial was terminated prematurely after enrollment of 39 patients (aCRT arm; n = 17, echo-guided BiV arm; n = 22) because of lower than expected enrollment. In the intention-to-treat analysis, the improvement of CCS was achieved in 10 patients (59%) in the aCRT arm (n = 17) and 16 patients (73%) in the echo-guided BiV arm (n = 22, p = 0.36). For the secondary endpoint, only 6-min walk distance was significantly greater in the aCRT arm than in the echo-guided BiV arm, and no difference was observed in the echocardiographic parameters. Heart failure hospitalization-free survival was also not significantly different (p = 0.91). There was no death during the follow-up. ConclusionsImprovement of CCS was similarly observed after aCRT and echo-guided BiV in CRT recipients with moderately wide LBBB and normal AV conduction. A prospective study is needed to explore the impact of CRT and pacing algorithm on Japanese patients with moderately wide LBBB.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.